We have developed and deployed within our operating rooms a system which provides real-time estimates of effectsite levels of inhalational anaesthetic agents along with forward predictions of end-tidal and effect-site concentrations. The initial aim of this project was to provide users of inhalational agents with tools similar to those available in target-controlled infusion systems. This paper describes the development and implementation of the system and outlines evaluation and uses of the system.
We have developed a system which provides estimates of effect-site levels of inhalational agents along with forward predictions of both the end-tidal and effect-site concentrations of these agents. These predictions are based on the past and current rate of agent delivery and measured end-tidal levels. The purpose of this paper is to outline the development, evaluation and uses of this system, which has been deployed in many of our operating theatres. Figure 1 shows the output of the system incorporated into a display which includes trend graphs and automated trend signalling, while Figure  2 provides a more detailed view of the volatile prediction components. Past and current effect-site concentrations are calculated using measured endtidal values and an appropriate end-tidal to effect-site t 1/2 . End-tidal predictions from these effect-site predictions are calculated from a model which takes total fresh gas flow and vaporisor dial settings as its primary inputs and models the progress of the anaesthetic. The model looks ahead 10 to 20 minutes using the current input values which are updated every 10 seconds.
This system is deployed in more than half the operating rooms in one hospital and has become an accepted component of the monitoring setup. It is useful as a monitoring tool and to guide inhalational anaesthesia delivery and also allows easy demonstration of the principles of inhalational kinetics and low flow anaesthesia.
An important part of local acceptance and adoption of the system is that it provides information that the anaesthetist can actively use, observe or ignore. The system does not require any changes to anaesthetic technique and in particular does not require use of a closed circuit. Thus, over time, anaesthetists develop an understanding of the information provided by the system. It provides the same information for inhalation agents as modern The left of the screen provides a graphical display of the majority of monitored parameters. This area scrolls to the left as data are added. Data are spread across four panels, to avoid overlap and clutter and to group related parameters. Although a graticule is provided for reference, the scales used differ amongst parameters (e.g. heart rate and blood pressure 0-200, SpO 2 0-100).
Scales are not provided, since the primary purpose is to illustrate trends or changes. Current values, on the right of the screen in the same colour as the relevant graph, provide reference values (see online version for colour reproduction of graphs The right of the screen shows the current value of the monitored and derived parameters. The output of the trend detection algorithm is shown (where relevant) as up to four "+" or "-" symbols depending on the magnitude and direction of the change. In this example increases in pulse rate and end-tidal sevoflurane are flagged.
The volatile prediction components of the display are explained in detail in Figure 2 . NIBP=non-invasive blood pressure, Sevo=sevoflurane, FGF=fresh gas flow.
target-controlled infusion devices do for intravenous agents.
Evolution of the system
The current system grew from a perceived need and a number of suitable ingredients. The underlying concept was to provide tools similar to those available in early target controlled infusion (TCI) pumps, and in particular, effect-site estimations and forward predictions. We had already developed an interest in trend display systems 1 , and were using a system which collected data from Datex™ CardioCap and Ultima monitors and displayed a series of trend graphs with a statistical trend detection algorithm 2 .
Our department purchased the first of its Datex AS/3 monitoring systems around 1993. These monitors have a different, more comprehensive data export protocol than the earlier Datex monitors and the trend display system was rewritten to access these devices. From 1996, the year in which TCI with the Diprifusor was launched at the World Congress in Sydney, the Datex anaesthesia delivery unit (ADU) began to be Figure 1 . The left side plots the historical trend of inspired and expired sevoflurane levels (solid region) along with the calculated effect-site level. The current time is at the right edge of the solid region. On the right is information from the anaesthesia delivery unit: fresh gas and vaporisor settings. In some versions the calculated rate of volatile use and cost are shown (see Figure 1 ). Below this is the current measured inspired and expired volatile along with 'MAC' fraction exported from the monitor. Estimated effect-site is labelled "Calc Brain" and in this example is 2.4 vol%. Below this are the forward predictions for end-tidal (FE) and effect (Brain) at 1, 2, 5 and 10 minutes. The predictions are also plotted for 10 minutes extending from the right of the current end-tidal and effect values, using the same time scale as the main display. This sequence shows the changes in fresh gas and volatile delivery over a 12-minute period. In the top panel the vaporiser dial has been set at 8% while fresh gas flow is 1.3 lpm. In the middle panel, the effect-site level has risen to near the desired target, fresh gas flow has been set to 340 ml/minute and the vaporisor turned off. Once the end-tidal had fallen to meet the (rising) effect-site concentration the vaporisor was turned on and increased to a value that predicted constant end-tidal and effect-site values which were then maintained as shown in the bottom panel. Sevo=sevoflurane, FGF=fresh gas flow. introduced to our operating theaters. These devices have electronic vapour control and share the same general data export scheme as the AS/3. This common interface made collecting data from these devices relatively straightforward. The third component was the availability of an anaesthetic uptake and distribution model. The model we use was originally developed by Heffernan as part of an engineering thesis as a teaching tool to demonstrate halothane uptake, and incorporated the effects of changes in ventilation and cardiac output on uptake 3 .
As with most models of inhalational agent uptake, this model is based on a number of compartments, in this case nine, representing various components of the body. These include lung, blood, brain, kidney, liver, fat and poorly perfused tissues. These compartmental models were generally derived as teaching tools and have frequently not been formally evaluated. One well known example is GasMan 4 , which has been used both for teaching and to derive practice guidelines 5 , and while still used for these purposes, has also never been evaluated.
As part of earlier work, this model had been extended to include a full range of inhalational agents 6 . The 'Heffernan' model has the particular advantage that it incorporates a circle circuit and does not assume a totally closed circuit with direct injection of liquid agent 7 .
This serendipitous combination of tools allowed us to collect gas flow and vapour setting data, 8 .
The assessment technique of Varvel et al 9 also generates two other variables; wobble, which measures the variability in the individual subject and divergence, which measures the drift over time. Although these variables are not part of the definitions of acceptable model performance, we consider divergence as least as important as MADPE and MDPE since much of anaesthesia administration involves titration to effect and a control system should maintain a relatively constant effect for a given input. This means that regardless of the actual level either in the model or the patient, the system should maintain that level when asked. An extension of this argument would suggest that bias, that is knowledge of the true value, is much less important than drift.
The finding that 'our' existing locally developed model performed well allowed us to use this model as the basis for a 'predictive' application, instead of needing to either develop and evaluate a new model or implement an alternative, validated model. This has allowed us to concentrate on developing and evaluating a clinical application rather than on model development, although we remain interested in the latter.
We began by developing an application which collected gas flow and vaporiser dial setting data from the ADU and used the model to simulate progress of the anaesthetic in real time. We then used a second 'instance' of the model which, at each 10 second iteration, takes the current model state, and assuming the current dial and fresh gas settings remain constant, runs forward 10 minutes in time to provide predictions of arterial and hence end-tidal levels. Details of the model 8 and our implementation 11 are described in detail in earlier publications. Figure 3 outlines the general flow of the application.
Our plan had been to include the ability for the user to input a range of dial settings directly into the computer so that the user could trial various settings. However, early experience showed us that the 10 second update time allowed the ADU vaporiser dial to be used directly for this purpose: the user can make several adjustments, see the result and rapidly iterate to an ideal solution. The actual dial setting soon becomes irrelevant, in much the same way that the infusion rate of propofol in ml/hour is unimportant in TCI delivery.
The volatile prediction application shared many common components with our existing trend display system and once the basic functionality was established the two were combined. This allowed the volatile prediction system to 'see' the measured end-tidal values. This information is used to scale the predictions to align the model output with the measured values. Thus the effect of drift in the model is overcome. The offset is also incorporated into the display.
As we were developing a working system, awareness of the value of effect-site targeting was increasing. We therefore worked to add this functionality to our system. Our initial approach was simply to use the 'brain' compartment of the underlying model as the 'effect-site'. Since the predictive instance of the model calculates values for all compartments, extracting the 'future' levels in the brain compartment was not complex.
We have more recently modified the determination of effect-site levels to a system based purely on measured (or predicted) end-tidal values combined with an appropriate half-time. This also allows us to easily change the t 1/2 within the system without adjusting the whole body model. Based on a study where we explored the interaction between changes in end-tidal sevoflurane and the bispectral index 12 , and the results of others 13 , we have settled on values of 3.2 minutes for sevoflurane and 2.8 minutes for desflurane as discussed below.
End-tidal arterial gradients
The actual definitions of effect-site time constants are based on the relationship between central compartment concentrations and some measure of effect. However, almost all estimates of inhalational agent effect-site kinetics utilise end-tidal values as an estimate of central compartment. Although differences between these compartments are well recognised 14, 15 , published data suggest that in most individuals the end-tidal to central compartment gradient remains relatively constant. This means that while inhaled effect-site parameters do not strictly parallel those for IV agents, determination of these parameters using end-tidal values do incorporate the end-tidal to central compartment difference.
Computing platform
The original version of the halothane uptake model was implemented in FORTRAN on a PDP-11 'mainframe' used with remote terminals 3 . The program was then ported to Lattice™C on a Commodore Amiga 6 .
The current project was developed and implemented on a wide range of Macintosh Computers running various versions of the 'Classic' operating system. Programming has been in Metrowerks 'C' using versions five through seven of the development platform. The trending application was developed primarily on a Powerbook 180c and deployed on various Powerbook 1xx models. Evaluation and development of the combined application utilised a PowerMac 8600.
Deployment of the volatile prediction application was originally on Apple Macintosh LC and Quadra 475 models in slim line 'pizza box' cases with 13 inch CRT displays. These were permanently mounted on the anaesthesia machines. These units were obtained secondhand at very low cost. The pizza box form is easy to mount on the ADU (Figure 4) and is amongst the last models with a truly mechanical power switch. This means that if power is disconnected, then reconnected, the computer will automatically restart. Over the past four years we have replaced these units with 'Mac Minis' with G4 processors. These machines run OS10.4 and our application runs in 'classic' mode. Automatic restart after a power failure is available as an operating system preference. We use KeySpan™ 28GX dual serial to universal serial bus convertors to interface the serial ports of the ADU and A/S3 to the computer. We now use 15 inch liquid crystal display monitors.
Interface changes
The original 'release' of the application required the user to restart the application for each patient and enter weight, which was used to scale compartment sizes in the model, and to select the agent in use. We observed that most anaesthetists did not do these entries, in part because the keyboard/mouse interface available at the time was difficult to position and use, and also they did not consider the system an essential component of the workplace. We removed the need to input the agent in use by implementing simple tests based on the information from the ADU. We also removed the need to enter patient weight and used a 'standard' patient, which was also assumed in the validation study. In contrast to intravenous agents such as propofol 16 and remifentanil 17 , the effect of covariates has not been studied in detail for models of inhalational uptake and there is a need for further work in this area. Several studies have failed to show an effect of patient weight on inhalational uptake 18,19. We are investigating ways in which the system could be used with other anaesthetic delivery systems. The key requirements are a measure of the total fresh gas flow and an estimate of the vaporisor dial setting. We are exploring various approaches to transducing the dial setting on conventional vaporisors.
Other inhalational agents
Our initial evaluation was performed with isoflurane and sevoflurane. We have also explored model performance with desflurane and to a limited extent enflurane and halothane. Of interest, published values for effect-site half-times of various agents are do not differ greatly. One recent study gives values of 3.6 minutes for both sevoflurane and isoflurane and 2.8 minutes for desflurane 20 . We have shown that differences of this size in the estimate of t 1/2 do not have a great effect on the time to equilibrium 21 . As might be expected, the differences in effect-site t 1/2 parallel known differences in tissue uptake rather than blood solubility.
For desflurane we found generally poor results with MDPE 78%, MADPE 77% and divergence of 10%/hour with considerable inter individual variability 22 . As we have discussed elsewhere the reasons for this poor performance are not clear to us and we note other models with much better performance have been published 23 .
Despite these results, desflurane is included in our system. Informal discussion with colleagues who regularly use desflurane in locations with the predictive display reveals general satisfaction with system performance. We speculate that this is, in part, because the 'divergence' or drift is relatively low: a drift of 10%/hour translates to less than 2% over a 10-minute period. This means that as suggested above, the system is of value in maintaining a given level and (possibly) in facilitating changes in levels.
We have performed a limited evaluation with enflurane and halothane. We were particularly interested in halothane since the uptake model we use was developed for halothane 24 . We also hoped that performance with a range of agents would provide pointers to the reasons why performance varies so much between agents. Unfortunately, the regulatory status of these drugs changed during the study and we were only able to collect data from limited numbers of patients (enflurane n=8, halothane n=4). With enflurane we found MDPE 11%, MADPE 29% and divergence -31%/hour while the corresponding results for halothane were MDPE 27%, MADPE 28% and divergence -39%/hour. With both agents MDPE and MADPE are at the upper limit of 'acceptable' while divergence is reasonably high, however the numbers are too small to allow definite conclusions to be drawn.
We continue to explore aspects of model performance, including the effect of covariates such as patient weight and in particular to try and determine the effect of various factors on model performance with each agent in the hope of improving understanding of models and gaining further insights into inhalational kinetics. We are particularly interested in finding ways to improve performance with desflurane and from this information attempt to determining which components of a model are critical for each agent. From this information we may gain further insights into the kinetics of inhalational agents.
In addition to fixed covariates such as age and weight, other factors that may change over short time periods, such as changes in ventilation and cardiac output, can be shown to influence uptake 25 , and presumably compartmental distribution of agents. Since it is possible to record a wide variety of routinely monitored parameters along with uptake data it should be possible to incorporate real time changes in physiology into models. However this will be a long-term project.
The redesigned software will incorporate the underlying model as a discrete module, which will allow for evaluation and implementation of a range of models.
Uses of the system
As noted, the system has become almost a routine part of clinical anaesthesia practice in our hospital. We continue to deploy additional units and are working towards a total re-implementation on a tablet-based system.
We maintain two discrete versions of the program; one for routine use and the other as a platform for ongoing evaluation and data collection for studies both related to use of the system itself and broader data collection applications. The 'clinical' version is installed on all permanently mounted machines and is set to start whenever the computer is restarted. This version requires no user input and automatically saves data from the previous four restarts so these are available for review if required, and can be configured to save specific data sets such as flow rates as required. The 'research' version allows the 'input' to be either on-line monitors, or a previously saved 'raw' data stream, which can be saved by this version. All monitored and derived parameters can be saved as spreadsheet-ready text, which allows detailed analysis for specific studies and evaluation of different versions and parameters of the model.
Ongoing evaluation
In addition to the value of our system as a clinical tool, we have been able to use it as a test bed to evaluate various components of the system, to study the utility of such systems and to explore other, more theoretical or basic science questions that have arisen during development. It has also provided a platform for evaluation of other aspects of anaesthesia care.
An ideal endpoint would be to show improved outcome or similar. We have explored surrogate endpoints and shown that users do make changes more rapidly when the display is present 11 . We have also demonstrated that fresh gas flow rates have decreased by over 30% in the past five years 26 . This decrease has occurred without an active feedback program and we like to speculate that the presence of the predictive display system has been part of this change. As shown in Figure 2 , determining the optimal vaporisor setting for a given fresh gas flow is straightforward, especially when combined with the trend display which makes slow changes in agent or gas concentration (e.g. O 2 ) rapidly apparent.
We have explored a number of aspects of the science underlying the system, including the model performance issues outlined above and the choice of appropriate effect-site half-times. We had noted that most studies into effect-site half-times are conducted with a single agent and in the absence of the confounding effects of surgery, or with major regional blockade 20 . We therefore investigated effectsite half-times during routine surgery and found a value of 3.2 minutes for sevoflurane 12 by determining the value for t 1/2 that minimised the hysteresis between the calculated effect-site and the measure of effect, in this case bispectral index. An incidental finding in this study was that the t 1/2 for the 'effect' of burst suppression is much longer (12 minutes). This result, combined with observations from effectguided anaesthesia and the work of others suggest that the range of effects of a given agent may have different values for t 1/2 s 27, 28 . A further implication of these studies is that end-tidal based 'MAC' values may be a poor guide to anaesthesia administration 29 .
The 'MAC' values required for a wide range of endpoints have been determined. By definition, these values are established after allowing time for equilibrium, or wash-in, to occur 30 . This should mean that effect-site levels and equilibrium end-tidal ('MAC') levels required for a given stimulus should be similar. Confirmation of this relationship would allow the user to 'target' specific effect-site levels at different stages of anaesthesia and surgery, thus overcoming the delay inherent in using end-tidal based 'targeting'. We have, for instance, demonstrated that patients first respond after surgery at mean levels approximately MAC-awake 31 .
Demonstrating the value of both effect-site control and forward prediction of inhaled agents also helps provide validity to devices appearing on the market, such as the General Electric Navigator and Dräger Smart Pilot View, which explore and display combined effects of multiple drugs 32, 33 .
Future studies
We have begun to explore the value of effectsite measures and control with volatile anaesthesic agents. In particular we are attempting to demonstrate that dynamically determined effect-site levels, as determined by systems such as described in this paper, relate to specific clinical endpoints. We are extending the work related to MAC levels to look at other effects and stimuli to help build up the sort of picture discussed above.
Summary
Over the past 10 to 15 years we have developed and implemented into routine clinical practice, a system that provides continuous estimates of effectsite concentrations and forward predictions of effectsite and end-tidal inhaled anaesthetic levels. This system has proved a useful clinical and research tool and we are working to provide evidence to support the value of these systems.
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